[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355205-105":59,"doc-detail-355205-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","exploring-the-gut-microbiome-and-metabolomic-interactions-of-antimetabolite-drugs-to-optimize-therapy","Exploring the gut microbiome and metabolomic interactions of antimetabolite drugs to optimize therapy","","Antimetabolite drugs are core treatments for cancers and autoimmune diseases, but systemic toxicity often limits their benefit due to drug-induced disruptions in gut microbiota. Predicting which patients will respond remains difficult. Evidence links gut microbiome composition with antimetabolite outcomes through complex bidirectional drug–microbe interactions. This review integrates effects of common antimetabolites on microbial communities and proposes a framework including pharmacokinetics, endogenous metabolites, immune modulation, and apoptotic pathway regulation to assess chemotherapy–microbiota interplay. It also discusses microbial biomarkers and microbiota-targeting strategies, emphasizing that metagenomics and real-time monitoring can support precise therapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/exploring-the-gut-microbiome-and-metabolomic-interactions-of-antimetabolite-drugs-to-optimize-therapy/355205/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/exploring-the-gut-microbiome-and-metabolomic-interactions-of-antimetabolite-drugs-to-optimize-therapy/355205.png","ImageObject",300,407,{"name":92,"@type":93},"Rowan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is gut microbiota dysbiosis a key clinical challenge for antimetabolite therapy?","Question",{"text":112,"@type":113},"Drug-induced disruptions in gut microbiota affect both treatment efficacy and toxicity, making patient response difficult to predict reliably.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which types of mechanisms does the review propose for chemotherapy–microbiota interactions?",{"text":117,"@type":113},"The review outlines a framework including pharmacokinetics, endogenous metabolite production, immune modulation, and apoptotic pathway modulation.",{"name":119,"@type":110,"acceptedAnswer":120},"How can gut microbiota and metabolites help optimize antimetabolite drug use?",{"text":121,"@type":113},"Microbiota profiling may improve prediction of drug efficacy, and manipulating microbial communities may enhance therapeutic outcomes; potential microbial biomarkers are also discussed.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355205,1790178224,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","REVIEW ARTICLE     \nExploring the gut microbiome and metabolomic interactions of antimetabolite drugs to optimize therapy  \nJingyang Chena, b, Yanan Wanga, b, Lei Xua, b, Xiaona Lia, b and Libo Zhaoa, b   \naDepartment of Pharmacy, Peking University Third Hospital, Beijing, People's Republic of China; bTherapeutic Drug Monitoring and Clinical Toxicology Center of Peking University, Beijing, People's Republic of China  \nABSTRACT  \nAntimetabolite drugs are cornerstones in treating various cancers and autoimmune diseases; however, their clinical utility is often hampered by systemic toxicity caused by drug-induced gut microbiota dysbiosis. Predicting patient responses remains a significant challenge. Several studies have highlighted the influence of gut microbiota on antimetabolite treatment outcomes, revealing complex bidirectional interactions between the drugs and microbial communities. This review synthesizes the effects of common antimetabolites (including 5-fluorouracil, methotrexate, gemcitabine, capecitabine, 6-mercaptopurine, and thioguanine) on gut microbial communities and outlinesa framework (pharmacokinetics, endogenous metabolite production, immune modulation, and apoptotic pathway modulation) for assessing chemotherapy-microbiota interactions. Additionally, potential microbial biomarkers for predicting treatment responsesand strategies for manipulating the gut microbiota to enhance therapeutic efficacy are discussed. Therefore, advances in methodologies such as metagenomics and real-time microbial monitoring will be essential for unraveling these interactions and promoting the precise application of antimetabolite drugs.  \nARTICLE HISTORY  \nReceived 18 April 2025 Revised 17 November 2025 Accepted 23 February 2026  \nKEYWORDS  \nAntimetabolite drugs; gut microbiota; efficacy; toxicity; biomarker; intervention  \n1. Introduction  \nAntimetabolite drugs are widely used chemotherapeutic agents that mimic the molecular structures of substances involved in nucleic acid synthesis, inhibiting cell division and proliferation. Antimetabolite drugs can be classified into five categories, based on the different target enzymes they inhibit: 1 thymidylate synthase (TS) inhibitors, such as 5-fluorouracil (5-FU);2 dihydrofolate reductase (DHFR) inhibitors, such as methotrexate (MTX);3 purine nucleotide interconversion inhibitors, such as mercaptopurine (6-MP);4 ribonucleotide reductase inhibitors, such as hydroxyurea; and 5 deoxyribonucleic acid (DNA) polymerase inhibitors, such as cytarabine. Owing to their broad cytotoxic activity, antimetabolite drugs are used to treat various malignancies (including colorectal cancer [CRC], breast cancer, leukemia, choriocarcinoma, and osteosarcoma) and inflammatory conditions (such as inflammatory bowel disease [IBD] and rheumatoid arthritis [RA]) . 1,2 This results in diverse adverse effects, including gastrointestinal, hepatic, pulmonary, neurological, and cardiotoxic effects.3,4 Persistent clinical challenges include treatmentinduced gut microbiota disruptions. This disruption affects drug efficacy and toxicity, making it difficult to reliably predict patient responses. Therefore, it is essential to understand the mechanisms underlying these phenomena.  \nRecent advances in next-generation sequencing (NGS) technologies have enhanced our understanding of the gut microbiota. Notably, the critical influence of the gut microbiota on the efficacy of chemotherapy agents has been highlighted.5,6 This has led to the emergence of the field of “pharmacomicrobiomics” to describe their interactions.7,8 Antimetabolite drugs interfere with nucleic acid synthesis, consequently altering the composition and function of the host microbiota. This altered microbial state influences  \nCONTACT Libo Zhao  [libozhao@bjmu.edu.cn](libozhao@bjmu.edu.cn); Xiaona Li  yjklxn@163.com  Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, People's Republic of China  \n Supplemental data for this article can","cbCaimwHFAKziKjb","https://ap.wps.com/l/cbCaimwHFAKziKjb","pdf",3278193,34,"English","# 1. Introduction\n## Antimetabolite drugs and clinical challenges\n## Pharmacomicrobiomics and rationale for the review\n# 2. Framework for chemotherapy–microbiota interactions\n## Drug-induced microbiota dysbiosis\n## Mechanistic pathways: pharmacokinetics, metabolism, immunity, apoptosis\n# 3. Microbial biomarkers and therapeutic modulation\n## Predicting treatment responses\n## Strategies to manipulate gut microbiota for improved efficacy\n# 4. Future directions\n## Metagenomics and real-time microbial monitoring","[{\"question\":\"Why is gut microbiota dysbiosis a key clinical challenge for antimetabolite therapy?\",\"answer\":\"Drug-induced disruptions in gut microbiota affect both treatment efficacy and toxicity, making patient response difficult to predict reliably.\"},{\"question\":\"Which types of mechanisms does the review propose for chemotherapy–microbiota interactions?\",\"answer\":\"The review outlines a framework including pharmacokinetics, endogenous metabolite production, immune modulation, and apoptotic pathway modulation.\"},{\"question\":\"How can gut microbiota and metabolites help optimize antimetabolite drug use?\",\"answer\":\"Microbiota profiling may improve prediction of drug efficacy, and manipulating microbial communities may enhance therapeutic outcomes; potential microbial biomarkers are also discussed.\"}]","Exploring the gut microbiome and metabolomic interactions of antimetabolite drugs to optimize therapy | PDF",1790116720,86,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/016b44cdab92742d5c5a20f7ce6713e5.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/34aefbb7be735221b40dc42f972528a7.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/502f4a34ea86f67fd894a26b294fba11.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5a23e391800d22a1952f4e31cdfaff5a.webp",980,1306]